𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development of inducible EIAV-based lentiviral vector packaging and producer cell lines

✍ Scribed by Stewart, H J; Leroux-Carlucci, M A; Sion, C J M; Mitrophanous, K A; Radcliffe, P A

Book ID
109855275
Publisher
Nature Publishing Group
Year
2009
Tongue
English
Weight
341 KB
Volume
16
Category
Article
ISSN
0969-7128

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development and characterization of a mi
Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors
✍ Seraphin Kuate; Ralf Wagner; Klaus Überla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB

## Abstract ## Background Lentiviral vectors allow gene transfer into non‐dividing cells. Further development of these vector systems requires stable packaging cell lines that enable adequate safety testing. ## Methods To generate a packaging cell line for vectors based on simian immunodeficienc

Generation of a packaging cell line for
Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector
✍ Yajin Ni; Susan Sun; Ibe Oparaocha; Laurent Humeau; Brian Davis; Reuben Cohen; G 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 573 KB

## Abstract ## Background An Erratum has been published for this article in Journal of Gene Medicine 7(6), 2005, 835. A stable packaging cell line facilitates large‐scale lentivirus vector manufacture. However, it has been difficult to produce clinical‐scale HIV‐1‐based lentiviral vectors using

Efficient transduction and selection of
Efficient transduction and selection of human T-lymphocytes with bicistronic Thy1/HSV1-TK retroviral vector produced by a human packaging cell line
✍ François M. Lemoine; Mariana Mesel-Lemoine; Mustapha Cherai; Géraldine Gallot; H 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 390 KB

## Abstract ## Background T‐cells expressing the HSV1‐TK suicide gene can be used for the control of graft‐versus‐host disease following allogeneic stem cell transplantation. To develop clinical trials based on such a strategy, we have generated under good manufacturing procedures a novel ‘split g